| Effect of a home-based wearable continuous ECG monitoring patch on detection of undiagnosed atrial fibrillation: the mSToPS randomized clinical trial SR Steinhubl, J Waalen, AM Edwards, LM Ariniello, RR Mehta, GS Ebner, ... Jama 320 (2), 146-155, 2018 | 427 | 2018 |
| A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin RJ Ferguson, SMF De Morais, S Benhamou, C Bouchardy, J Blaisdell, ... Journal of Pharmacology and Experimental Therapeutics 284 (1), 356-361, 1998 | 280 | 1998 |
| Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban S Tamayo, W Frank Peacock, M Patel, N Sicignano, KP Hopf, LE Fields, ... Clinical cardiology 38 (2), 63-68, 2015 | 201 | 2015 |
| Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber MU Zafar, DA Vorchheimer, J Gaztanaga, M Velez, D Yadegar, ... Thrombosis and Haemostasis 98 (10), 883-888, 2007 | 155 | 2007 |
| Role of hydrazine in the mechanism of isoniazid hepatotoxicity in rabbits TC Sarich, M Youssefi, T Zhou, SP Adams, RA Wall, JM Wright Archives of toxicology 70, 835-840, 1996 | 149 | 1996 |
| Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor TC Sarich, SP Adams, G Petricca, JM Wright Journal of Pharmacology and Experimental Therapeutics 289 (2), 695-702, 1999 | 140 | 1999 |
| Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers M Wolzt, M Levi, TC Sarich, SL Boström, UG Eriksson, ... Thrombosis and haemostasis 91 (06), 1090-1096, 2004 | 107 | 2004 |
| Effects of JNJ‐38431055, a novel GPR119 receptor agonist, in randomized, double‐blind, placebo‐controlled studies in subjects with type 2 diabetes LB Katz, JJ Gambale, PL Rothenberg, SR Vanapalli, N Vaccaro, L Xi, ... Diabetes, Obesity and Metabolism 14 (8), 709-716, 2012 | 105 | 2012 |
| A model of isoniazid-induced hepatotoxicity in rabbits TC Sarich, T Zhou, SP Adams, AI Bain, RA Wall, JM Wright Journal of pharmacological and toxicological methods 34 (2), 109-116, 1995 | 102 | 1995 |
| Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects TC Sarich, M Wolzt, UG Eriksson, C Mattsson, A Schmidt, S Elg, ... Journal of the American College of Cardiology 41 (4), 557-564, 2003 | 98 | 2003 |
| Factors indicating intention to vaccinate with a COVID-19 vaccine among older US adults J Nikolovski, M Koldijk, GJ Weverling, J Spertus, M Turakhia, L Saxon, ... PloS one 16 (5), e0251963, 2021 | 88 | 2021 |
| Novel oral anticoagulants and reversal agents: considerations for clinical development TC Sarich, JH Seltzer, SD Berkowitz, JT Curnutte, CM Gibson, M Hoffman, ... American Heart Journal 169 (6), 751-757, 2015 | 83 | 2015 |
| The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S‐mephenytoin T Sarich, T Kalhorn, S Magee, F Al‐Sayegh, S Adams, J Slattery, ... Clinical Pharmacology & Therapeutics 62 (1), 21-28, 1997 | 83 | 1997 |
| No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran TC Sarich, R Teng, GR Peters, M Wollbratt, R Homolka, M Svensson, ... Clinical pharmacokinetics 42, 485-492, 2003 | 75 | 2003 |
| Rationale and design of a home-based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted population: The mHealth Screening To Prevent Strokes … SR Steinhubl, RR Mehta, GS Ebner, MM Ballesteros, J Waalen, ... American heart journal 175, 77-85, 2016 | 66 | 2016 |
| Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects TC Sarich, UG Eriksson, C Mattsson, M Wolzt, L Frison, G Fager, ... Thrombosis and haemostasis 87 (02), 300-305, 2002 | 66 | 2002 |
| Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube KT Moore, MA Krook, S Vaidyanathan, TC Sarich, CV Damaraju, ... Clinical pharmacology in drug development 3 (4), 321-327, 2014 | 55 | 2014 |
| Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male … SL Boström, GFH Hansson, M Kjaer, TC Sarich Blood coagulation & fibrinolysis 14 (5), 457-462, 2003 | 53 | 2003 |
| Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ‐38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects LB Katz, JJ Gambale, PL Rothenberg, SR Vanapalli, N Vaccaro, L Xi, ... Clinical Pharmacology & Therapeutics 90 (5), 685-692, 2011 | 51 | 2011 |
| Torcetrapib produces endothelial dysfunction independent of cholesteryl ester transfer protein inhibition MA Connelly, TJ Parry, EC Giardino, Z Huang, W Cheung, C Chen, ... Journal of cardiovascular pharmacology 55 (5), 459-468, 2010 | 49 | 2010 |
Ulf G ErikssonRIA TA Lead Quantitative Clinical Pharmacology, AstraZenecaVerified email at astrazeneca.com
